Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company (Lilly) has released new results from an observational substudy from TRITON-TIMI 38 which showed that patients treated with Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel).
Subscribe to our email newsletter
Lilly said that Effient analysis involved 346 patients with acute coronary syndrome (ACS) who had received either study drug and subsequently underwent isolated CABG at some point during the 15-month TRITON-TIMI 38 trial.
Additionally, to all-cause mortality, this same analysis found that the risk-adjusted rate of cardiovascular death at 30 days was also lower in patients treated with Effient compared with those receiving clopidogrel.
Reportedly, Effient-treated patients experienced a higher volume of chest tube blood loss at 12 hours post-CABG compared to the clopidogrel-treated patients.
Duke University Medical Center Cardiovascular and Thoracic Surgery division chief and lead investigator for the retrospective CABG analysis Peter Smith said that the analysis showed that Effient was associated with a lower mortality rate compared with clopidogrel among these CABG patients but with a significantly higher risk of serious bleeding events.